ENVISION SUMMIT 2024

COORDINATION

Dr. Mafalda Oliveira, Hospital Vall d’Hebron/VHIO, Barcelona and President of SOLTI
Dr. Juan M. Ferrero-Cafiero, Chief Scientific Development Officer at SOLTI

AGENDA

10:00 | Welcome
Coordinators

10:10 | Improving outcomes in early HER2-negative breast cancer: new drugs, new combinations, new scenarios
Dr. David Cescon (Princess Margaret Cancer Centre, Toronto)

10:40 | Discussion
Coordinators

10:55 | Optimizing endocrine treatment in advanced ER+/HER2-negative breast cancer with new agents, combinations and strategies
Dr. François Clement Bidard (Institut Curie & UVSQ/Université Paris-Saclay, Paris)

11:25 | Discussion
Coordinators

11:40 | Break

12:10 | New generation of liquid biomarkers to detect minimal residual disease: sensitivity, limit of detection, and prediction of relapse. Where do we go from here?
Dr. Isaac Garcia-Murillas (Institute of Cancer Research, London)

12:40 | Discussion
Coordinators

12:55 | Multiomic approaches for biomarker discovery in metastatic breast cancer
Dr. Christine Desmedt (Katholieke Universiteit, Leuven)

13:25 | Discussion
Coordinators

13:40 | Conclusions
Coordinators

13:45 | Lunch + Satellite symposium